Introduction {#s1}
============

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer death in the United States. In 2010, approximately 142,000 people were diagnosed with CRC, and about 40% of these patients presented with advanced disease [@pone.0038422-Mnejja1]. Treatment for advanced CRC with chemotherapy is typically intended for disease control and palliation of symptoms only, and as a result, unresectable CRC remains an incurable disease. In order to improve clinical outcomes and develop new therapeutic approaches, the development of a reliable preclinical model to study CRC biology and drug sensitivities is required.

Mouse models of CRC remain one of the most useful tools to decipher the biological mechanisms underlying the oncogenic process. To date, a variety of genetically-engineered, carcinogen-induced and xenograft mouse models have been established [@pone.0038422-Uronis1], [@pone.0038422-Richmond1] and it is generally agreed that no one model is sufficient to elucidate all aspects of CRC etiology.

Genetically engineered mouse (GEM) models have been invaluable in establishing the role of many different genetic mutations and signal transduction pathways contributing to the oncogenic process and allow investigation in the context of an active immune system [@pone.0038422-Uronis1], [@pone.0038422-Richmond1]. However, many of these GEM models, primarily those involving mutation of the *APC* tumor suppressor gene, develop tumors in the small intestine rather than the colon. This makes longitudinal disease progression studies difficult in addition to lacking the genetic complexity observed in human cancers [@pone.0038422-Uronis1], [@pone.0038422-Richmond1].

Another widely used mouse models of CRC relies on the use of carcinogens to induce colorectal tumor development. Perhaps the most widely used carcinogen-based model is the Azoxymethane (AOM) model. Here, colorectal tumor development is initiated by AOM, a potent, colon-specific carcinogen through the formation of DNA adducts [@pone.0038422-Druckrey1]. Colorectal tumors derived using this model recapitulate key human pathological features observed in humans and allow investigation of the early stages of CRC. However tumor initiation and development is a time consuming process, often taking up to 6 months with tumor multiplicity and penetrance depending heavily on the mouse strain [@pone.0038422-Uronis1], [@pone.0038422-Papanikolaou1], [@pone.0038422-Kaiser1].

While GEM and carcinogen-based models have significantly enhanced our knowledge of the genetics and etiology of CRC, these models do not allow for accurate testing of cancer therapeutics to be used in the clinical setting [@pone.0038422-Kerbel1]. The most widely utilized *in vivo* model for the testing of anti-cancer drug efficacy and combinations is the xenograft model. Historically, xenografts have been established through the subcutaneous injection of genetically-defined human-derived cell lines into immune-compromised nude mice [@pone.0038422-Kendall1]. However, to date, the majority of these cell line-based xenograft models have failed to generate drug sensitivity data that translates into clinically relevant information [@pone.0038422-Kerbel1]. In addition, recent reports suggest that tumor-stroma interactions not present in cell line-based xenografts may represent an integral component in oncogenic potential and tumor drug response [@pone.0038422-Loeffler1], [@pone.0038422-Harris1]. Therefore, more recently, whole-tissue explants derived from human cancers including breast [@pone.0038422-Marangoni1], lung [@pone.0038422-Fichtner1], prostate [@pone.0038422-Pretlow1] and colorectal cancer [@pone.0038422-Arcaroli1]--[@pone.0038422-Fichtner2] have been established in an attempt to generate more clinically accurate and reliable xenograft models. However, these studies examined mainly early passage explants (\<5 generations) from predominantly primary tumors and therefore there remains the need to further characterize these models and evaluate how well they retain important characteristics of the original human tumor especially in metastatic disease.
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###### Sites from which PDCCEs were derived.
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  Sample ID    Anatomic Location
  ----------- -------------------
  CRC020             Liver
  CRC025             Liver
  CRC028             Colon
  CRC030             Colon
  CRC034             Liver
  CRC039             Liver
  CRC040             Liver
  CRC043             Liver
  CRC054             Liver
  CRC057             Lung
  CRC066             Colon
  CRC075             Liver
  CRC083             Lung
  CRC093            Omentum
  CRC096             Colon
  CRC102             Liver
  CRC103          Peritoneum
  CRC105             Colon
  CRC108             Liver
  CRC119             Liver
  CRC120             Liver
  CRC133             Lung
  CRC149             Liver
  CRC159             Lung
  CRC162             Liver
  CRC167             Liver
  CRC170             Liver

![PDCCE tumor pathology is retained after 11 generations in mice.\
H&E stained sections of two independent well-differentiated adenocarcinomas (CRC039 and CRC075) show that tumor architecture remains similar after 11 passages in NOD/SCID mice. Images shown are at 20× magnification.](pone.0038422.g001){#pone-0038422-g001}
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###### Histological comparison of patient tumor and PDCCEs.
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  Sample ID    Source    Generation   %Tumor   %Necrosis   %Stroma   %Tumor Gland Formation               Histologic Type
  ----------- --------- ------------ -------- ----------- --------- ------------------------ -----------------------------------------
  CRC008       Patient                  65         5         25                80                       Adenocarcinoma, NOS
                PDCCE       3rd         70        10         20                70                       Adenocarcinoma, NOS
  CRC028       Patient                  10        80         10                40                  Adenocarcinoma w/signet ring
                PDCCE       1st         25         5         70                40                  Adenocarcinoma w/signet ring
  CRC034       Patient                  65         0         35                80                       Adenocarcinoma, NOS
                PDCCE       1st         85         5         10                75                       Adenocarcinoma, NOS
  CRC039       Patient                  10         0         90                50                    Adenocarcinoma w/mucinous
                PDCCE       1st         60         0         40                70                    Adenocarcinoma w/mucinous
                PDCCE       6th         25        65         10                60                    Adenocarcinoma w/mucinous
                PDCCE       10th        35        50         15                80                    Adenocarcinoma w/mucinous
  CRC057       Patient                  25        45         20                80                       Adenocarcinoma, NOS
                PDCCE       1st         40        60          0                80                       Adenocarcinoma, NOS
                PDCCE       5th         50        35         15                80                       Adenocarcinoma, NOS
  CRC066       Patient                  25        45         30                80                       Adenocarcinoma, NOS
                PDCCE       1st         20         5         75                50                       Adenocarcinoma, NOS
  CRC075       Patient                  35        30         25                90                       Adenocarcinoma, NOS
                PDCCE       1st         50        15         35                95                       Adenocarcinoma, NOS
                PDCCE       5th         85         5         10                75                       Adenocarcinoma, NOS
                PDCCE       11th        65        10         25                70                       Adenocarcinoma, NOS
  CRC093       Patient                  15        30         55                60                       Adenocarcinoma, NOS
                PDCCE       1st         65        30          5                80                       Adenocarcinoma, NOS
                PDCCE       5th         80        10         10                85                       Adenocarcinoma, NOS
  CRC096       Patient                  20        65         15                65                       Adenocarcinoma, NOS
                PDCCE       14th        65        30          5                90                       Adenocarcinoma, NOS
  CRC102       Patient                  10        70         20                60                       Adenocarcinoma, NOS
                PDCCE       1st         80         3         17                80                       Adenocarcinoma, NOS
  CRC103       Patient                  5         40         55               100                       Adenocarcinoma, NOS
                PDCCE       1st         10        90          0                95                       Adenocarcinoma, NOS
                PDCCE       6th         10        90          0                95                       Adenocarcinoma, NOS
  CRC120       Patient                  35         0         65                50             Adenocarcinoma w/signet ring & mucinous
                PDCCE       1st         85         0         15                70                  Adenocarcinoma w/signet ring
  CRC133       Patient                  65        10         15                90                       Adenocarcinoma, NOS
                PDCCE       7th         10        85          5                80                       Adenocarcinoma, NOS
  CRC149       Patient                  25        60         15                80                       Adenocarcinoma, NOS
                PDCCE       1st         40        55          5                70                       Adenocarcinoma, NOS
  CRC170       Patient                  10        40         50                90                       Adenocarcinoma, NOS
                PDCCE       2nd         80         5         15                80                       Adenocarcinoma, NOS

![PDCCEs retain nuclear CDX2 expression and signet ring morphology observed in original patient tumors.\
A. Representative PDCCE (CRC039) retains nuclear CDX2 expression after 11 generations in mice. Images shown are at 20× magnification. B. Early passage PDCCEs retain signet ring morphology observed in original patient colorectal tumor. Images shown are at 40× magnification. C. Xenografts generated from WiDr and HT29 CRC cell lines lack histological features consistent with patient-derived explants including the presence of stroma and the formation of glands. Images shown are at 20× magnification.](pone.0038422.g002){#pone-0038422-g002}

In this study, we have performed a more comprehensive molecular and histological analysis of a panel of 27 matched patient-derived colorectal cancer explants (PDCCEs) from both primary and metastatic sites as an extension of our previous work [@pone.0038422-Kim1] in which we compared the gene expression profile of 14 matched PDCCEs and their corresponding human tumors. We now demonstrate that PDCCEs retain global gene expression patterns, oncogene mutation status and histological parameters present in the original human cancers. Altogether these findings suggest that PDCCEs have the potential to serve as a reliable preclinical model that can be used to develop and characterize new therapeutic targets for patients with CRC.

Materials and Methods {#s2}
=====================

Tumor Samples/Ethics Statement {#s2a}
------------------------------

A total of 27 human samples were obtained for genomic and histological analysis. All patients provided written consent to have tissue stored and used for research. Samples used for analysis in the laboratory were de-identified and not linked with any personal health information (PHI). All parts of this study were approved by the Duke Institutional Review Board. All animal studies were performed under a Duke University Institutional Animal Care and Use Committee (IACUC) approved protocol.

![Patient tumor tissues and matched PDCCEs exhibit similar gene expression patterns.\
Unsupervised cluster analysis of 27 patient tumor-PDCCE matched pairs show that 22 pairs (81%) fell within the same cluster and 18 matched PDCCE (66%) clustered directly in pairs with the original patient tumor (gray boxes). Sample names containing an X denote PDCCE (xenograft) samples. The number immediately following the X indicates the generation/passage number of that particular sample.](pone.0038422.g003){#pone-0038422-g003}

Generation of Patient-Derived Colorectal Cancer Explants (PDCCEs) {#s2b}
-----------------------------------------------------------------

Colorectal tumors (both primary and metastatic) at time of surgery were collected under a Duke IRB approved protocol (Pro00002435). The tissues were washed with phosphate buffered saline (PBS) and then minced into pieces approximately ∼2 mm in size and injected into the flanks of 4-week-old NOD.CB17-PrkdcSCID-J mice obtained from Jackson Laboratories under a Duke IACUC approved protocol. Mice were observed and tumors measured with vernier calipers until the volume of the tumor ((V = L×2W×0.52 (L  =  longest diameter, W  =  shortest diameter)) reached ∼1,000 mm^3^. Tumors were then harvested, minced and re-implanted as described above until stable PDCCEs were established. At each generation, tumors were harvested and either fixed in 10% neutral buffered formalin (NBF), snap frozen in liquid nitrogen or frozen in optimal cutting temperature (OCT) medium on dry ice for further analysis.

10.1371/journal.pone.0038422.t003

###### Patient-derived colorectal cancer explants' *KRAS* and *BRAF* mutation status.
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  Sample ID              *KRAS* Status             *BRAF* status
  ----------- ----------------------------------- ---------------
  CRC020       WT (patient); C12 GGT\>GCT(mouse)        WT
  CRC025                      WT                        WT
  CRC028                      WT                        WT
  CRC030                      WT                        WT
  CRC034                      WT                        WT
  CRC039                 C12 GGT\>GCT                   WT
  CRC040                      WT                        WT
  CRC043                 C12 GGT\> AGT                  WT
  CRC054                 C12 GGT\>GAT                   WT
  CRC057                 C12 GGT\>GAT                   WT
  CRC066                      WT                        WT
  CRC075                      WT                        WT
  CRC083                 C12 GGT\>TGT                   WT
  CRC093                      WT                        WT
  CRC096                 C12 GGT\>GCT                   WT
  CRC102                      WT                        WT
  CRC103                 C12 GGT\>GTT                   WT
  CRC105                 C13 GGC\>GAC                   WT
  CRC108                      WT                        WT
  CRC119                 C12 GGT\>GTT                   WT
  CRC120                      WT                        WT
  CRC133                      WT                        WT
  CRC149                      WT                        WT
  CRC159                 C12 GGT\>AGT                   WT
  CRC162                      WT                        WT
  CRC167                 C12 GGT\>GCT                   WT
  CRC170                 C13 GGC\>GAC                   WT

Histological Preparation and Examination {#s2c}
----------------------------------------

Paraffin-embedded PDCCE tissues were sectioned in 6 µm intervals and stained with hemotoxylin and eosin (H&E). Each sample was evaluated by a trained pathologist for the following histological criteria: histologic type, CDX-2 positivity, and relative percentage of tumor, necrosis, stroma, tumor gland formation and CDX-2 positive nuclei. All tissues were examined using \>10 high-powered fields per section. Tumor nuclei were evaluated for CDX-2 staining using a standard quantitative scale of 0, 1+, 2+ and 3+. Staining of tumor nuclei at 2+ and 3+ was considered positive and all cases considered positive exhibited at least 20% of tumor nuclei with staining.

Oncogene Mutation Analysis {#s2d}
--------------------------

Genomic DNA was isolated from snap frozen PDCCE tissues using a Qiagen genomic DNA isolation kit. Samples were diluted to 10 ng/µl and PCR was performed using the following primers for *KRAS*: forward 5′ GTGTGACATGTTCTAATATAGTCA 3′; reverse 5′ GAATGGTCCTGCACCAGTAA 3′ and *BRAF*: forward 5′ TCATAATGCTTGCTCTGATAGGA 3′; reverse 5′ GGCCAAAAATTTAATCAGTGGA 3′. Amplicons were sequenced by conventional methods using the forward primers.

Microarray Analysis {#s2e}
-------------------

RNA was isolated from snap-frozen PDCCE tissues using a Qiagen RNA/DNA Allprep kit, converted to cDNA and labeled by one cycle IVT. IVT labeled cDNAs were prepared according to the manufacturer's instructions, and targets hybridized to the Human U133A 2.0 GeneChip and read on an Affymetrix array scanner. Raw data was converted to. CEL files and RMA normalized. CEL files (GSE35144) are available at the Gene Expression Omnibus (GEO) data repository (<http://www.ncbi.nlm.nih.gov/geo/>). To check for sample outliers and batch effects, 3D principal components analysis of the global gene expression was performed. Batch effects were normalized using the ComBat algorithm (<http://jlab.byu.edu/ComBat/>) [@pone.0038422-Johnson1]. Unsupervised hierarchical clustering of the human tumors and matching PDCCEs was performed on the 20% of genes with the greatest coefficient of variation. Agglomerative clusters were generated using the pearson correlation coefficient and complete linkage using the R program (The R Foundation for Statistical Computing).

Software Used for Analysis {#s2f}
--------------------------

The R statistical software package is available at [www.r-project.org](http://www.r-project.org). The Bioconductor R package is available at [www.bioconductor.org](http://www.bioconductor.org). ComBat is available as an R script at <http://jlab.byu.edu/ComBat/>. Graphpad Prism is a product of Graphpad Software (La Jolla, CA, USA) and is available at [www.graphpad.com/prism/prism.htm](http://www.graphpad.com/prism/prism.htm).

Results {#s3}
=======

Histological Evaluation of PDCCEs {#s3a}
---------------------------------

A panel of 27 patient-derived colorectal cancer explants (PDCCEs) by direct transplantation of human colorectal cancer (CRC) tissues into NOD-SCID mice was created in this study. [Table 1](#pone-0038422-t001){ref-type="table"} shows the origin of the patient tumor and a total of 5 primary PDCCEs and 22 metastatic PDCCEs were generated. To assess the extent to which *in vivo* models of patient-derived colorectal cancer explants (PDCEEs) accurately recapitulate and can therefore serve as a model of the human condition, we investigated whether PDCCEs retain key biological features inherent to individual human colorectal cancers (CRC) over time. First, to evaluate the extent to which histological parameters are retained after xeno-transplantation, two independent PDCCEs were passaged through \>10 generations and evaluated histologically. Both PDCCEs examined exhibited pathological features remarkably consistent with the original patient tumor through 11 generations ([Figure 1](#pone-0038422-g001){ref-type="fig"}). Next, a comprehensive histological evaluation performed on a sub-panel of 15 matched PDCCEs and original banked tissues revealed that 15/15 PDCCEs retained pathological features similar to those observed in the matched human tumor and were characterized as histologically identical to their matched original banked sample ([Table 2](#pone-0038422-t002){ref-type="table"}). Even after 11 generations, PDCCEs retained the ability to form glands and contained CDX-2 positive nuclei comparable to the first generation PDCCEs ([Figure 2](#pone-0038422-g002){ref-type="fig"}). These data demonstrate that the histological features present in colorectal cancer, including the formation of glands and presence of stromal components are retained even in late passage explants, suggesting that unlike CRC cell line-derived xenografts, the PDCCE model provides us with a research tool that recapitulates the human condition generally not observed in other models.

PDCCEs Retain Basic Global Gene Expression Profiles Inherent to Human Colorectal Cancers {#s3b}
----------------------------------------------------------------------------------------

Next, to further evaluate the extent to which PDCCEs represent their primary human counterparts, we analyzed 27 matched patient tumors and PDCCEs by microarray analysis. Patient tumor and PDCCE gene expression data was first normalized using ComBat to minimize batch effects. Unsupervised hierarchical clustering analysis was then performed on the normalized data set and revealed three distinct clusters ([Figure 3](#pone-0038422-g003){ref-type="fig"}). Of the 27 matched patient tumor and PDCCEs, 22 pairs (81%) fell within the same cluster based on the dendrogram and 18 PDCCEs (66%) clustered directly with the original tumor sample. Altogether, these data suggest that basic global gene-expression patterns are preserved between PDCCEs and their original human counterparts.

Oncogene Mutation Status is Retained in PDCCEs {#s3c}
----------------------------------------------

For patients with advanced colorectal cancer, the testing of mutation status of oncogenes such as *KRAS* is required for guiding therapy. Specifically, patients with *KRAS* mutations show no benefit from treatment with EGFR inhibitors such as cetuximab or panitumumab, while patients whose tumors are *KRAS* WT derive benefit from anti-EGFR based therapies [@pone.0038422-Adelstein1], [@pone.0038422-Douillard1]. To determine whether these clinically-significant genomic parameters are maintained in PDCCEs, 27 matched PDCCEs and original patient samples were analyzed for *KRAS* and *BRAF* mutation status. Of the 27 matched pairs evaluated, 13 presented with activating *KRAS* mutations (codon 12 = 11; Codon 13 = 2) ([Table 3](#pone-0038422-t003){ref-type="table"}). Of these 27 matched pairs, 26/27 PDCCEs (96%) matched their original human counterpart suggesting that human colorectal cancer tissues maintained as mouse PDCCEs are genetically stable and retain oncogenic mutation status critical to CRC pathophysiology. All samples tested negative for *BRAF* mutations. Altogether, these data suggest that PDCCEs maintain the biologically complex histological, gene expression and mutation-based characteristics observed in human CRCs.

Discussion {#s4}
==========

To date, a number of mouse xenograft models have been established to investigate CRC etiology and treatment. To a large extent, these models have been generated using late passage cell lines derived from human CRCs and while significant treatment-induced tumor responses have been observed in these models, they are rarely predictive of tumor response in human patients [@pone.0038422-Kerbel1]. This is likely due in these models, at least in part, to the inherent lack of stroma in tumor-derived epithelial cell lines. Mounting evidence indicates that paracrine signaling and extracellular matrix components supplied by neighboring stromal cells play a significant role in the oncogenic potential of colorectal carcinoma and that modulation of these stromal interactions directly impact the efficacy of chemotherapy on tumor response [@pone.0038422-Loeffler1], [@pone.0038422-Harris1].

Recent attempts have been made to generate mouse xenograft models of CRC by direct transplantation of human colon tumors into immune-compromised mice [@pone.0038422-Arcaroli1]--[@pone.0038422-Fichtner2], [@pone.0038422-Mischek1]. Poupon and coworkers reported that the passage of human colon cancer tissues through a xenograft stage significantly improves the success rate of cell line derivation from human CRC metastases [@pone.0038422-DanglesMarie1]. More recently, Hohenadl and coworkers reported that histological characteristics and oncogene expression levels are retained in early passage CRC xenografts [@pone.0038422-Mischek1] while Fichtner et al., and Messersmith et al, used panels of 15- and 10 human CRC explants respectively to evaluate drug sensitivity [@pone.0038422-Arcaroli1], [@pone.0038422-Fichtner2]. Additionally, these studies used patient-derived explants mainly from the primary site and as metastatic tumors tend to be more aggressive and are more likely to differentiate, it remains unclear if PDCCEs generated from metastatic sites would maintain similarity to the original tumor. While these studies have begun to underscore the value of explant models in CRC research, a more comprehensive histological and molecular analysis on a larger panel of human CRC explants are needed to justify their use as a preclinical model to perform accurate drug efficacy analysis and predictive biomarker identification.

In this study, we demonstrate that PDCCEs generated from human adenocarcinomas with varying histological features each retain the parameters of the tumor from which they were derived at the histological, global RNA expression and oncogene mutation levels. Despite the existence of differences in the percentage of tumor stroma present between the original human tissues and those xenografted into mice, our study focuses on the malignant epithelial cells. First, the histological architecture inherent to colorectal adenocarcinoma, primarily the ability to form dysplastic glands as well as the presence of CDX-2 positive nuclei is maintained in the PDCCEs throughout multiple passages (\>10). Next, we compared the gene expression profiles between matched PDCCEs and its corresponding patient tumor and observed that 18/27 (66%) of the samples clustered directly together and 22/27 (81%) clustered within the major cluster as defined by the dendrogram.

We speculate that the 9 PDCCE samples that did not cluster directly with their corresponding original tumor may have been due to the inherent heterogeneous nature of CRC. It is plausible that the original CRC tumor samples corresponding to these 9 PDCCEs harbored small sub-populations bearing additional oncogenic events. This would in turn confer a growth advantage to these populations after being transplanted into the mouse, causing the PDCCE to have a different genetic composition than the original tissue from which it was derived. In support of this notion, it appears that most variation between the primary tumor and its PDCCE occur in early PDCCE passages and that less variation occurs through the process of passaging. For example, PDCCE CRC105 clustered with the original patient sample at PDCCE passages 1 and 11 while PDCCE CRC149 did not cluster with its original sample at either passage 1 or 5 suggesting that genetic changes occur predominantly in early passages and are maintained through later passages. It is also possible, that in these 9 samples, there may have been a greater stromal contamination resulting in a difference in their clustering pattern. These results suggest that there are indeed intrinsic differences between the matched patient tumor and PDCCE and extrapolations drawn from these models must be done so carefully. However, overall our findings suggest that the PDCCE model has the potential to be used in the investigation of new therapeutic agents that target both the malignant epithelial tumor architecture and/or stromal component and that PDCCEs can be maintained for 10 or more generations while retaining key histological parameters.

Finally, we evaluated the *KRAS* and *BRAF* mutation status of the PDCCEs and showed that the status of all but one of the oncogene mutations was retained. We observed one case (CRC020) in which a *KRAS* activating mutation was present in the PDCCE but was not detected in the original patient samples despite the fact that these samples clustered together by unsupervised cluster analysis. It is most likely that a small, undetectable population of *KRAS* mutant cells was present in the patients tumor at the time of surgical resection and that the growth advantage conferred by *KRAS* activation allowed for subsequent expansion of *KRAS* mutant cells during early PDCCE passages.

Although any single mouse model will never fully recapitulate actual findings in patients, the use of preclinical models is necessary and practical for the development of therapeutic agents and biomarkers and a crucial first step in bringing these agents to the clinic. We do realize the limitations of our model and that any finding must undergo rigorous testing to gauge its accuracy, reliability, and reproducibility and must also be retrospectively validated in multiple patient samples. Nevertheless we feel that our preclinical mouse model has the potential to be used to identify and test novel combinations of therapeutic agents and to also develop both predictive and prognostic biomarkers, which can then be systematically brought forth into the clinical setting.
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